Advaxis Receives IRB Approval For Cervical Dysplasia Trial Of ADXS11-001
Links shared publicly online about this topic.
- 1,640total visits
Advaxis Receives IRB Approval For Cervical Dysplasia Trial Of ADXS11-001
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, has received approval from the New England Institutional Review Board (IRB) to enroll
View full resource at medicalnewstoday.com
Tags: Biotech
Most Recently Shared on October 30, 2009 at 3:51 am By:
Advaxis Receives IRB Approval For Cervical Dysplasia Trial Of ADXS11-001: Advaxis, Inc., (OTCBB: ADXS), the liv.. http://bit.ly/3FAAYG
Advertisement
